IQVIA Holdings (LTS:0JDM) DeferredTaxAndRevenue: $2,261 Mil (As of Mar. 2026)


LTS:0JDM IQVIA Holdings Inc LTS:0JDM
86 GF Score
Price $207.00
GF Value $248.80
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is IQVIA Holdings DeferredTaxAndRevenue?

IQVIA Holdings LTS:0JDM -0.36% 86 DeferredTaxAndRevenue is $2,261 Mil as of Mar. 2026. GuruFocus rates LTS:0JDM with a GF Score™ of 86/100 and a GF Value™ of $248.80 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

IQVIA Holdings's current deferred tax and revenue for the quarter that ended in Mar. 2026 was $2,261 Mil.

IQVIA Holdings DeferredTaxAndRevenue Related Terms

IQVIA Holdings DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for IQVIA Holdings's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IQVIA Holdings DeferredTaxAndRevenue Chart

IQVIA Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,825.00 1,797.00 1,799.00 1,779.00 2,118.00

IQVIA Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,940.00 2,123.00 2,160.00 2,118.00 2,261.00
LTS:0JDM
86GF Score
IQVIA Holdings Inc LTS:0JDM
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $2,261 Mil mean?
IQVIA Holdings (LTS:0JDM) has a DeferredTaxAndRevenue of $2,261 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on IQVIA Holdings.
Is IQVIA Holdings' DeferredTaxAndRevenue too high?
IQVIA Holdings' current DeferredTaxAndRevenue is $2,261 Mil. Overall, IQVIA Holdings has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' DeferredTaxAndRevenue compare to WAT and ILMN?
IQVIA Holdings' DeferredTaxAndRevenue of $2,261 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Medical Diagnostics & Research company?
A good DeferredTaxAndRevenue depends on the Medical Diagnostics & Research industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on IQVIA Holdings. IQVIA Holdings's current DeferredTaxAndRevenue is $2,261 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Modestly Undervalued. The stock's GF Value™ is $248.80, compared to a current price of $207.00 — trading 16.8% below its estimated fair value. The current DeferredTaxAndRevenue is $2,261 Mil. IQVIA Holdings' overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current DeferredTaxAndRevenue is $2,261 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?

Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued. The current stock price of $207.00 is trading 16.8% below its estimated GF Value™ of $248.80. GuruFocus considers IQVIA Holdings to be Modestly Undervalued.

Key valuation signals for LTS:0JDM:

  • DeferredTaxAndRevenue: $2,261 Mil
  • GF Value™: $248.80 vs. price of $207.00 (16.8% below fair value)
  • GF Score™: 86/100 with 3 warning signs

No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IQVIA Holdings Business Description

Address 2400 Ellis Road, Durham, NC, USA, 27703
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
86GF Score

Get the complete analysis for LTS:0JDM

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$207.00
Price
$248.80
GF Value